To confirm the efficacy of post-transplant cyclophosphamide (PTCy) combined with everolimus as GvHD prophylaxis in patients with refractory aggressive lymphomas, specifically focusing on T- and B-cell types.
Key Findings:
Donor engraftment achieved in all patients, indicating successful transplantation.
AGvHD occurred in 63.6% of patients; 33.3% had grade II, and 6.1% had grade III and IV, highlighting the need for effective GvHD management.
CGvHD developed in 21.2% of patients, with 9.1% on systemic immunosuppression, suggesting a need for ongoing monitoring.
OS was 64% at 1 and 2 years; PFS was 58% and 55% at year 1 and 2, respectively, demonstrating promising survival rates.
GRFS was 54% at 1 year and 48% at 2 years, indicating the potential effectiveness of the treatment regimen.
Interpretation:
The combination of PTCy and everolimus shows promising outcomes in managing GvHD and improving survival rates in refractory lymphoma patients, aligning with findings from the OCTET-EVER trial and suggesting implications for clinical practice.
Limitations:
Retrospective design may introduce bias, affecting the reliability of results.
Small sample size limits generalizability of findings to broader populations.
Higher NRM compared to previous trials may affect outcomes and warrant further investigation.
Conclusion:
The study supports the efficacy of PTCy and everolimus in reducing GvHD and improving survival in refractory lymphomas, warranting further investigation in larger, prospective trials to validate these findings.
by Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel, Philipp Gödel, Moritz Fürstenau, Pascal Nieper, Till Braun, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick
The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago
